Scarica l'app Stockscreener
3.24
2.11%
-0.07
Dopo l'orario di chiusura:
3.28
0.04
+1.23%
Voyager Therapeutics Inc Borsa (VYGR) Ultime notizie
Is Voyager Therapeutics Inc. a good long term investmentTremendous wealth creation - PrintWeekIndia
How high can Voyager Therapeutics Inc. stock price go in 2025Rapid return acceleration - jammulinksnews.com
What drives Voyager Therapeutics Inc. stock priceFree Capital Efficiency Planning - Autocar Professional
What analysts say about Voyager Therapeutics Inc. stockMarket-leading growth rates - jammulinksnews.com
Voyager Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
Why Voyager Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Stock Analysis - Newser
Voyager Therapeutics’ Promising Alzheimer’s Study: A Potential Game-Changer? - MSN
Voyager Therapeutics: A High-Conviction Biotech Play in the Tau-Targeting Alzheimer's Revolution - AInvest
Why did Voyager's net profit surge in Q4 2024 despite high operating expenses? - AInvest
Does Voyager Therapeutics Inc. stock pay reliable dividendsTrend Based Entry Alerts - beatles.ru
Baird Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
Voyager Therapeutics adds new gene therapy to Alzheimer’s program - BioWorld MedTech
Baird reiterates Outperform rating on Voyager Therapeutics stock with $18 price target - Investing.com Canada
Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11 - 富途牛牛
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease - GlobeNewswire
How Voyager Therapeutics Inc. stock performs during market volatilityDaily Top Gainers - Newser
Voyager Therapeutics Introduces New Program Targeting Genetic Risk Factor of Alzheimer's Disease - 富途牛牛
Voyager Therapeutics Launches New Gene Therapy Program Targeting APOE for Alzheimer's Disease Treatment - Quiver Quantitative
Voyager Therapeutics unveils APOE-targeting Alzheimer’s therapy program By Investing.com - Investing.com South Africa
Voyager Therapeutics unveils APOE-targeting Alzheimer’s therapy program - Investing.com
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.
What makes Voyager Therapeutics Inc. stock price move sharplyBreakout Setup Scanner - Newser
Allspring Global Investments Holdings LLC Buys 21,149 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Brokerages - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by Rhumbline Advisers - Defense World
Financial Comparison: Prime Medicine (NYSE:PRME) & Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics at H.C. Wainwright: Genetic Innovation in Focus By Investing.com - Investing.com Canada
Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspecti - GuruFocus
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | VYGR Stock News - GuruFocus
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):